New insights into SMA pathogenesis: immune dysfunction and neuroinflammation

Marc-Olivier Deguise & Rashmi Kothary

1Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Ontario K1H 8L6, Canada
2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada
3Centre for Neuromuscular Disease, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada
4Department of Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada

Correspondence
Rashmi Kothary, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada, K1H 8L6. Tel: (613) 737-8707; Fax: (613) 737-8803; E-mail: rkothary@ohri.ca

Funding Information
This work was supported by Cure SMA/Families of SMA Canada; Muscular Dystrophy Association (USA) (grant number 294568); Canadian Institutes of Health Research (CIHR) (grant number MOP-130279); and the E-Rare-2 program from the CIHR (grant number ERL-138414). M-O.D was supported by a Frederick Banting and Charles Best CIHR Doctoral Research Award.

Received: 24 April 2017; Accepted: 25 April 2017

Annals of Clinical and Translational Neurology 2017; 4(7): 522–530
doi: 10.1002/acn3.423

Spinal muscular atrophy as a multi-organ disorder

Spinal muscular atrophy (SMA) is a devastating neuromuscular disorder clinically characterized by paralysis and muscle weakness. It affects 1 in 6000 to 10,000 live births, making it one of the most deadly genetic disorders in infants. In 1995, the genetic basis of SMA was shown to be due to mutations or deletions of the Survival Motor Neuron 1 (SMN1) gene. The encoded protein, termed SMN, is ubiquitous and complete knock out is embryonic lethal. Consistent with this, SMA is not a disease of complete absence of the SMN protein but rather due to the low basal levels of SMN produced by a second nearly identical copy of SMN1, termed the SMN2 gene.

The preferential susceptibility of motor neurons to low levels of SMN is still poorly understood. However, in the last 5 years, a number of studies have highlighted abnormalities in other cell types in SMA (reviewed in). In addition, studies have highlighted the benefit of systemic delivery of therapeutic compounds when compared to CNS restricted delivery on the phenotypic amelioration in preclinical studies. Altogether, SMA is emerging as a multi-organ disorder rather than simply a motor neuron disease per se.

Lymphoid organ defects are a consistent feature in different SMA mouse models

This past year has marked a major development into the contribution of immune organ defects to SMA pathogenesis. Indeed, our group along with two others has independently published a whole array of abnormalities in
immune organs, such as the spleen and thymus, in different SMA mouse models (Fig. 1).9–11 The first striking abnormality in the lymphoid organs consists of a considerable reduction in spleen size, which was observed in four SMA mouse models of different severity.9–11 Interestingly, the reduction in spleen size was noted before any motor impairment, with the milder Smn2B/+ model showing the most drastic splenic atrophy.11 Similarly, the spleen architecture was disrupted in three out of four SMA mouse models. Reduction of red pulp area, loss of clear white and red pulp borders and loss of B-cell follicles were described.9–11 Increased fibrotic tissue and abnormal accumulation of smooth muscle cells were also noted.9,11 Interestingly, the most severe mouse model, termed Smn−/−;SMN2, did not show any structural abnormalities.11 This might be due to its limited lifespan, which may not permit the full phenotype to develop. These defects might be particularly clinically relevant since SMA type 1 patient necropsies showed an array of splenic abnormalities such as accessory spleens, congested red pulp and increased numbers of precursors.9

The reasons behind the small spleen sizes in the SMA mouse models are not clear. Proliferation of cells in the spleen appeared abnormal only at late stages in the Taiwanese SMA model mice, while it remained unchanged in the SmnΔ7 mice.9,10 Investigation of cell death revealed very little change in the Taiwanese model.9 Vasculature abnormalities were reported in other organs and could have been the initial trigger.12,13 Immunostaining of blood vessels markers revealed very little change in the spleens of Taiwanese and SmnΔ7 mice.9,10 However, the Smn2B/+ spleens displayed increased necrosis on gross morphological observation, which may suggest abnormal blood flow.11 In a similar manner, smooth muscle cell clumping observed in these spleens may be due to abnormal vasculature.11

The thymus was examined in Smn2B/+ and the Smn−/−; SMN2 mice, although no significant differences in size were observed.11 Nonetheless, the histological structure in the thymus showed cortex thinning and increased apoptotic bodies in these two mouse models of SMA.11 As the thymus is primarily responsible for T-cell maturation, it was proposed that T-cells might be stalled in maturation, leading to smaller spleens. T-cell development was abnormal at late stages of the disease, but relatively normal at presymptomatic stages.11 This infers that the defects in the thymus are either a consequence of abnormalities in the spleen and the periphery, or a totally independent process.

Importantly, these processes appeared mediated by SMN. Firstly, SMN levels in wild type spleen and thymus were strikingly high, at par or higher than in spinal cord and considerably higher than in skeletal muscles.11 Secondly, ubiquitous introduction of one copy of SMN2 in the Smn2B/+ mice rescued splenic and thymic phenotype.11 In a similar manner, intracerebroventricular injection of antisense oligonucleotides also abrogated the splenic defects in the SmnΔ7 spleens.10 The latter findings highlight the potential importance of autonomic nerve fibers in triggering lymphoid organ defects.

**Potential functional consequences of lymphoid organ defects in SMA**

Primary lymphoid organs include the bone marrow and the thymus. These organs are involved in immune cell maturation. Secondary lymphoid organs include the spleen, the lymph nodes and mucosal-associated lymphoid tissues (MALT) (Peyer’s patches, adenoids, tonsils and others - reviewed in14). These organs act as sentinels against foreign bodies and antigens that could be harmful to our bodies. The spleen has a wider array of functions, including filtrating senescent red blood cells out of the circulation, iron homeostasis, and acting as a reservoir for platelets, red blood cells and white blood cells (Fig. 2).15 Defects in any one of these organs could lead to great functional consequences as detailed below.
Immunity

It is likely that the multiple abnormalities observed in the lymphoid organs of the SMA mice result in immune impairment. The structure of the spleen is crucial for its function. For example, the incoming blood goes through the marginal zone, where many macrophages and B-cells act to filter the blood for foreign antigens. Moreover, the spleen contains unique subsets of specialized macrophages that have better recognition for certain pathogens. Indeed, this places the spleen as a major player in the clearance of encapsulated bacteria like *Mycobacterium tuberculosis* and *Streptococcus pneumoniae*, but also of *Staphylococcus aureus*, and potentially of viruses. Moreover, asplenic patients are immunodeficient, are recommended to be on a more stringent immunization schedule, and more aggressive clinical management is initiated at an earlier stage when facing fever or infection.

In SMA mouse models, the decreased spleen size and the disrupted splenic structure is likely to result in impaired immune functions against pathogens. Additionally, loss of B-cell follicles, diminished circulating lymphocytes, and abnormal T-cell maturation are in keeping with this possibility. The fact that SMA patients also harbor various splenic abnormalities, highlights that this phenomenon is also relevant to human patients. It is interesting to note that early reports described atrophic Waldeyer’s ring and cervical lymph nodes in addition to impaired cell-mediated immunity, as assessed by lymphocyte transformation and skin test, in clinically diagnosed SMA patients. Accordingly, many SMA patients had nonmucocutaneous candidiasis, which usually only occurs in immunodeficient individuals. Moreover, pulmonary infection, especially pneumonia, appears to be a common feature of SMA patients. Decreased respiratory efficiency and stasis of secretions can increase risk of infections. For this reason, superimposed immunodeficiency has not previously been considered as contributory to the disease etiology but may indeed play a major role in the presentation of chronic pulmonary infection in SMA patients. Nonetheless, evidence in human SMA patients remains sparse at the moment and more research is warranted on this aspect to better understand whether murine defects are reflective of true human pathology.

Many areas of the immune system remain unexplored in the context of SMA. The lymph nodes, bone marrow and MALTs are lymphoid tissues that have yet to be investigated. Of importance, lymph nodes are distributed all over the body and abnormalities in this tissue could lead to impaired antigen screening, impacting immunity as a whole. Similarly, the bone marrow is responsible for B-cell and myeloid cell (monocytes, erythrocytes, neutrophils and others) development and alterations in maturation of these cells could also be detrimental. Indeed, B-cell follicle loss in the spleen may be related to bone marrow deficiency. Given that T-cell maturation defects were identified, it would not be surprising to uncover similar features in the bone marrow. Furthermore, the blood circulating immune cells were not deeply studied either. Future endeavors should aim at expanding our knowledge on the role of other organs of the immune system in SMA pathogenesis, and decipher whether SMA mice and patients can correctly mount an immune response to a variety of pathogens that include both bacteria and viruses. Of course, retrospective clinical studies should also aim at discovering over-represented pathogens causing infections in the SMA patient population and their likelihood of infections in comparison to healthy individuals to ensure enhanced care is provided if needed. The recent efforts identifying the immune organ defects have offered limited mechanistic insights. The mechanism leading to the most prominent defect, the small spleens, remained to be determined. Possible explanations include abnormal vasculature, denervation, and...
cell-intrinsic defects, which have all been previously identified in other organs (Fig. 2). However, other possibilities also include lack of proliferation or increased apoptosis, which seem unlikely based on current observations, and abnormal expression of homing chemokines.

Iron homeostasis
The spleen is also involved in blood filtration and iron homeostasis. Strikingly, macrophages involved in iron recycling are depleted in SMA. However, splenic iron metabolism was not investigated in the latter study. Interestingly, impaired liver development, iron overload and embryonic lethality were the main features of Smn conditional knockout restricted to the liver. Recently, iron homeostasis defects were also observed in the Taiwanese mouse model of SMA. Whether the spleen is causative of iron dysregulation, and potential cross-talk between the liver and the spleen exists to regulate the pool of iron remains to be determined.

Status of neuroinflammation in ALS and SMA
Neuroinflammation is a well established characteristic of neurodegenerative disorders. This process is mainly mediated by astrocyte, microglia and T-cells. Defective immune organs, and more particularly a potentially defective T-cell compartment, might signal defective inflammatory response in SMA, an aspect that has so far not been studied in the field (Fig. 3). Indeed, after over 20 years of innovative research, the events triggering motor neuron death in SMA remain elusive. It is interesting to note that lymphoid organs, and more specifically the spleen, may actively participate in the process of neurodegeneration. ALS, an adult onset motor neuron disorder, has received attention from the SMA community for their possible common molecular ties in disease pathogenesis. Whether or not SMA and ALS actually have similar underlying molecular mechanism, neuroinflammation is an important part of disease pathogenesis in ALS, and the lack of research in this aspect in SMA warrants further investigation.

What have we learned from the ALS field?
Neuroinflammation research in ALS has gained considerable ground since reports described microglial and astrocytic activation features, as well as presence of lymphocytes in necropsies of ALS patients. These findings have been confirmed numerous times both in humans and mutant SOD1 (mSOD1) mouse models.

Microglia came under thorough scrutiny for their possible involvement in disease pathogenesis. Indeed, it appears that the timing of their activation and proliferation occur in the rapidly progressing phase of motor neuron degeneration. Interestingly, diminution of mSOD1 restricted to microglia leads to slower disease progression and extends survival considerably. In a similar manner, wild type bone marrow transfer in either lethally irradiated mSOD1 or mSOD1; PU.1−/− mice leads to slower progression and increased survival. These changes were suggested to be conferred by wild type microglial cells. However, these reports did not take into account that donor wild type lymphoid cells, like T-cells, may also contribute to the beneficial effect. In vitro, mSOD1 microglia release more pro-inflammatory cytokines like IL-1β and TNFα, superoxide, but less neuroprotective IGF1. Moreover, when cocultured with motor neurons, microglia could cause cell death. While much of the information points toward significant microglial contribution to disease, other reports have argued otherwise. Similarly, minocycline, a tetracycline derivative that has anti-inflammatory properties in addition to off-target inhibition of microglial activation, showed promise in preclinical models of ALS but failed in clinical trial.
T-cell presence is usually minimal in the CNS. However, under pathological circumstances, they can infiltrate the spinal cord. In the mSOD1 mouse model, T-cells infiltrate the spinal cord at a time point associated with microglial activation, highlighting the potential synergy of these cells in disease in a mouse model of ALS. In this context, T-cells appear particularly protective. Importantly, hybridizing RAG2 onto the mSOD1 mice, creating ALS mice without any T-cells or B-cells, lead to severe worsening of disease progression. Similar results are also obtained with double mutant CD4−/− mSOD1 mice. Mechanistically, CD4 T-cells appear to mediate microglial activation and their absence resulted in increased cytotoxic markers and diminished neuroprotective markers. Of interest, adoptive transfer of activated regulatory T-cells or effector T-cells from wild type mice into mSOD1 recipients leads to delayed motor symptoms and extended survival. Moreover, regulatory T-cells are associated with slow progressing phases in mSOD1 mice and are negatively correlated with rapid progression in ALS patients. Nonetheless, it appears that mSOD1 T-cells are not functionally impaired. Contrastingly, B-cells were not found to be present in the spinal cords of ALS mouse models and complete ablation of B-cells did not change the disease phenotype.

Astrocytic activation is also present in multiple regions of the spinal cord and brain in ALS patients and mouse models, and is associated with motor neuron loss. Importantly, reduction of mSOD1 restricted to astrocytes slowed disease progression, in a similar manner as with microglial restricted mSOD1 reduction, likely attributed to inhibition of microglial activation. In fact, conditioned media from mSOD1 astrocytes is toxic to motor neurons in vitro. In vivo, astrocytes may mediate a neurotoxic environment because of their lowered expression of EAAT2 (or GLT-1 in mice), a glutamate transporter able to clear glutamate surplus in the synaptic space. Interestingly, T-cells also seem to have some effect on astrocytic function and proper expression of GLT1. The full array of changes in astrocytes is beyond the scope of this manuscript but this has recently been reviewed. It is interesting to note that the kinetics of action of astrocytes, microglia and T-cells and their interactions are orchestrated with the rate of disease progression in ALS. For example, Th-2 T-cells and M2 microglia molecular anti-inflammatory profiles are associated with slow progressing phase of ALS course, which eventually convert to a predominantly Th-1 T-cell and M1 microglial proinflammatory response mediating the rapidly progressing phase (reviewed in ).

Like SMA, peripheral immune alterations are also present in ALS. Spleens become smaller and their histological architecture is mildly disrupted at symptomatic age in mSOD1 mice. Interestingly, increased cell death and diminished T-cell proliferation were also described. Moreover, increased activated circulating macrophages, abnormal numbers of CD4 T-cells, antibodies and circulating immune complex have been described in blood of ALS patients, but the results have been inconsistent. Interestingly, the development of C9orf72 null mouse models, after identification of a mutated version of this gene in a significant proportion of ALS patients, did not lead to overt motor impairment. Instead, an array of peripheral immune organ abnormalities arose, including splenomegaly, lymphadenopathy and eventually an autoimmune-like phenotype. Nonetheless, macrophages and microglia appeared particularly susceptible, showing lysosomal dysfunction and a proinflammatory state. Strikingly, transcriptomic analysis of spinal cord reveals similar changes in pathways involved in immune function both in mice and C9orf72 ALS patients, likely leading to neuroinflammation.

Current status of our understanding of neuroinflammation in SMA

In the context of SMA, neuroinflammation has never been thoroughly investigated (Fig. 3). In contrast to ALS, microglia and T-cells have been mainly overlooked while some reports have highlighted the contributions of astrocytes to disease pathogenesis. More specifically, increased astrogliosis was observed in necropsies of patients and in the SmnΔ7 mouse model at both presymptomatic and symptomatic stages. SMA patient induced pluripotent stem cell-derived astrocytes revealed abnormal calcium regulation, decreased glial cell-derived neurotrophic factor (GDNF) production but normal GLT1 expression. There is no doubt that astrocyte intrinsic abnormalities contribute to SMA pathogenesis, however their link to neuroinflammation and motor neuron death has not been determined. SMN restoration restricted to the astrocyte compartment significantly increased lifespan and motor behavior, but did not improve motor neuron survival. More related to the context of neuroinflammation, pro-inflammatory cytokines could be elevated in SMA patients and mouse models. Microglial activation has been observed in the SmnΔ7 mouse model but not in the more severe Smn−/−;SMN2 mice. To our knowledge, there is no information on the contribution of microglia to neuroinflammation and to SMA pathogenesis (Fig. 3). The involvement of T-cells in spinal cord has never been studied and their involvement in neuroinflammation in the context of SMA remains unknown.

Despite the paucity of information, it is very likely that neuroinflammation has a significant contribution to SMA disease onset or progression. At the moment, the very few
reports on astrocytes are focused on cell-autonomous dys-function and its relation to motor neurons while emphasis on its overall relationship with other glial cells in the potential neuroinflammatory CNS milieu is overlooked (Fig. 3). Given the importance of microglia on ALS progression, an in-depth analysis of the significance of microglia in SMA is warranted. Importantly, functional studies investigating the status of microglial activation (M1 - proinflammatory or M2 - anti-inflammatory) over time may give us insight on pathways that can be modulated to halt or reduce progression. With the recent reports concerning peripheral immune organ abnormalities and T-cell maturation dysfunction in SMA mouse models, it is possible that intrinsic T-cell alterations result in an abnormal neuroinflammatory response and exacerbation of disease. Investigation of the status of T-cells in the spinal cord and whether they exhibit a protective or cytotoxic function in SMA will be of interest.

**New perspectives for SMA**

The defective peripheral immune organs in SMA preclinical models raise several important questions that will need to be addressed. How do immune organs become affected by SMN depletion? What are the functional consequences of defective immune organs, more particularly on immunity and neuroinflammation? Do patients show similar immune system abnormalities? With the most recent FDA approval of nusinersen (Spinraza), which represents the first approved drug for the treatment of SMA, it will be instrumental to continue to understand disease etiology. Indeed, while the results of the nusinersen clinical trial looked promising, the treated patients still lag far behind healthy individuals on motor functions. Thus, it is critical to understand and target various pathways involved in SMA pathogenesis that may not currently be covered with Spinraza (restricted to the CNS), such as the peripheral immune organs. Establishing the pathogenic status of peripheral immune system as well as neuroinflammation in the context of SMA will be of critical importance in this context.

**Acknowledgments**

We would like to thank Servier for the artwork (Servier Medical art - http://servier.com/Powerpoint-image-bank). This work was supported by Cure SMA/Families of SMA Canada; Muscular Dystrophy Association (USA) (grant number 294568); Canadian Institutes of Health Research (CIHR) (grant number MOP-130279); and the E-Rare-2 program from the CIHR (grant number ERL-138414). M-O.D was supported by a Frederick Banting and Charles Best CIHR Doctoral Research Award.

**Author Contribution**

MOD and RK wrote manuscript.

**Conflict of Interest**

None.

**References**

1. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978;15:409–413.
2. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155–165.
3. Schrank B, Götz R, Gunnersen JM, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci 1997;94:9920–9925.
4. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci 1999;96:6307–6311.
5. Deguise MO, Patitucci TN, Ebert AD, et al. Spinal Muscular Atrophy: disease Mechanisms and Therapy, 1st ed. London: Elsevier, 2017:167–190.
6. Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 2013;19:40–50.
7. Hua Y, Liu YH, Sahashi K, Rigo F. Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev 2015;29:288–297.
8. Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011;478:123–126.
9. Thomson AK, Somers E, Powis RA, et al. Survival of motor neurone protein is required for normal postnatal development of the spleen. J Anat 2017 Feb;230:337–346.
10. Khairallah MT, Astroski J, Custer SK, et al. SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of Spinal Muscular Atrophy. Hum Mol Genet 2012;21:941–951.
11. Deguise MO, De Repentigny Y, McFall E, et al. Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice. Hum Mol Genet 2017;26:801–819.
12. Shababi M, Habibi J, Yang HT, et al. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet 2010;19:4059–4071.
13. Somers E, Stenzel Z, Wishart TM, et al. Density, calibre and ramification of muscle capillaries are altered in a
mouse model of severe spinal muscular atrophy. Neuroumuscul Disord 2012;22:435–442.
14. Randall TD, Mebius RE. The development and function of mucosal lymphoid tissues: a balancing act with micro-organisms. Mucosal Immunol 2014;3:455–466.
15. Tarantino G, Scalera A, Finelli C. Liver-spleen axis: intersection between immunity, infections and metabolism. W J Gastroenterol 2013;19:3534–3542.
16. Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005;5:606–616.
17. Kang Y-SS, Yamazaki S, Iyoda T, et al. SIGN-R1, a novel C-type lectin expressed by marginal zone macrophages in spleen, mediates uptake of the polysaccharide dextran. Int Immunol 2003;15:177–186.
18. Kang YS, Kim JY, Bruening SA, et al. The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of mouse spleen. Proc Natl Acad Sci 2004 Jan 06;101:215–220.
19. Geijtenbeek TB, Groot PC, Nolte MA, et al. Marginal zone macrophages express a murine homologue of DC-SIGN that captures blood-borne antigens in vivo. Blood 2002;100:2908–2916.
20. Elomaa O, Kangas M, Sahlberg C, et al. Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell 1995;80:603–609.
21. Amlot PL, Hayes AE. Impaired human antibody response to the thymus-independent antigen, DNP-Ficoll, after splenectomy. Implications for post-splenectomy infections. Lancet 1985;1:1008–1011.
22. Davies JM, Lewis MP, Wimperis J, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haematology-Oncology task force. Br J Haematol 2011 Nov;155:308–317.
23. Ryniewicz B, Pawinska M. Preliminary immunological studies in spinal muscular atrophy. Eur J Pediatr 1978 May 22;128:57–60.
24. Migaj M, Janowicz W, Krajewska G, et al. Evaluation of cell-mediated and humoral immunity in children suffering from spinal muscular atrophy. Arch Immunol Ther Exp 1986;34:561–567.
25. Bach JR. Medical considerations of long-term survival of Werdnig-Hoffmann disease. Am J Phys Med Rehabil 2007;86:349–355.
26. Wang CH, Finkel RS, Bertini ES, Schroth M. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007;22:1027–1049.
27. Ge X, Bai J, Lu Y, et al. The natural history of infant spinal muscular atrophy in China: a study of 237 patients. J Child Neurol 2012;27:471–477.
28. Cobben JM, Lemmink HH, Snoeck I, et al. Survival in SMA type I: a prospective analysis of 34 consecutive cases. Neuroumuscul Disord 2008;18:541–544.
29. Mannaa MM, Kalra M, Wong B, et al. Survival probabilities of patients with childhood spinal muscle atrophy. J Clin Neuroumuscul Dis 2009;10:85–89.
30. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016;388:3017–3026.
31. Gormley MC. Respiratory management of spinal muscular atrophy type 2. J Neurosci Nurs 2014;46:E33–E41.
32. Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 2007;7:105–117.
33. Boyer JG, Deguise MO, Murray LM, et al. Myogenic program dysregulation is contributory to disease pathogenesis in spinal muscular atrophy. Hum Mol Genet 2014;23:4249–4259.
34. Heier CR, Satta R, Lutz C, DiDonato CJ. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet 2010;19:3906–3918.
35. Vitte JMM, Davout B, Roblot N, et al. Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload. Am J Pathol 2004;165:1731–1741.
36. Sznunyogova E, Zhou H, Maxwell GK, et al. Survival Motor Neuron (SMN) protein is required for normal mouse liver development. Sci Rep 2016;6:34635.
37. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science 2016;353:777–783.
38. Cappellano G, Carecchio M, Fleetwood T, et al. Immunology and inflammation in neurodegenerative diseases. Am J Neuropsychol 2012;3:89–107.
39. Ajmo CT Jr, Vernon DO, Collier L, et al. The spleen contributes to stroke-induced neurodegeneration. J Neurosci Res 2008;86:2227–2234.
40. Yamazaki T, Chen S, Yu Y, et al. FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep 2012;2:799–806.
41. Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 1990;47:1210–1216.
42. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992;140:691–707.
43. Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 1993;50:30–36.
44. Schiffer D, Cordera S, Cavalla P, Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1996;139(Suppl):27–33.
45. Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001;57:1282–1289.
46. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998;23:249–256.
47. Boillée S, Yamanaka K, Lobsiger CS. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006;312:1389–1392.
48. Corti S, Locatelli F, Donadoni C, et al. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain 2004;127(Pt 11):2518–2532.
49. Beers DR, Henkel JS, Xiao Q, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci 2006;103:16021–16026.
50. Weydt P, Yuen EC, Ransom BR, Moller T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 2004;48:179–182.
51. Xiao Q, Zhao W, Beers DR, et al. Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J Neurochem 2007;102(Pt 11):2518–2532.
52. Gowing G, Philips T, Van Wijmeersch B, et al. Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. J Neurosci 2008;28:10234–10244.
53. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. NeuroReport 2002;13:1067–1070.
54. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045–1053.
55. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991 Feb;28:254–260.
56. Chiu IM, Chen A, Zheng Y, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci 2008;105:17913–17918.
57. Beers DR, Henkel JS, Zhao W, et al. CD4 + T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci 2008;105:15558–15563.
58. Beers DR, Henkel JS, Zhao W, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011;134 (Pt 5):1293–1314.
59. Banerjee R, Mosley RL, Reynolds AD, et al. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS ONE 2008;3:e2740. https://doi.org/10.1371/journal.pone.0002740.
60. Henkel JS, Beers DR, Wen S, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med 2013;5:64–79.
61. Zhao W, Beers DR, Liao B, et al. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis 2012;48:418–428.
62. Naor S, Keren Z, Branshtein T, et al. Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J Neurol 2009;256:1228–1235.
63. Nagy D, Kato T, Kushner PD. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J Neurosci Res 1994;38:336–347.
64. Yamanaka K, Chun SJ, Boillée S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008;11:251–253.
65. Di Giorgio FP, Carrasco MA, Siao MC, et al. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 2007;10:608–614.
66. Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci 2002;99:1604–1609.
67. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73–77.
68. Vargas MR, Johnson JA. Astroglisis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics 2010;7:471–481.
69. Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol 2013;8:888–899.
70. Zhang R, Gascon R, Miller RG, et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2005;159:215–224.
71. Chen X, Feng W, Huang R, et al. Evidence for peripheral immune activation in amyotrophic lateral sclerosis. J Neurol Sci 2014;347:90–95.
72. Atanasio A, Decman V, White D, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep 2016;6:23204.
73. O’Rourke JG, Bogdanik L, Yáñez A, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science 2016;351:1324–1329.
74. Kuru S, Sakai M, Konagaya M, et al. An autopsy case of spinal muscular atrophy type III (Kugelberg-Welander disease). Neuropathology 2009;29:63–67.
75. Rindt H, Feng Z, Mazzasette C, et al. Astrocytes influence the severity of spinal muscular atrophy. Hum Mol Genet 2015;24:4094–4102.
76. Dachs E, Hereu M, Piedrafita L, et al. Defective neuromuscular junction organization and postnatal myogenesis in mice with severe spinal muscular atrophy. J Neuropathol Exp Neurol 2011;70:444–461.
77. Tarabal O, Caraballo-Miralles V, Cardona-Rossinyol A, et al. Mechanisms involved in spinal cord central synapse loss in a mouse model of spinal muscular atrophy. J Neuropathol Exp Neurol 2014;73:519–535.
78. McGivern JV, Patitucci TN, Nord JA, et al. Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia 2013;61:1418–1428.
79. Zhou C, Feng Z. Ko C-PP. Defects in Motoneuron-Astrocyte Interactions in Spinal Muscular Atrophy. J Neurosci 2016;36:2543–2553.
80. Ling KK, Lin MY, Zingg B, et al. Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. PLoS ONE 2010;5:e15457.